Drug Profile
Ross River virus vaccine - National Resilience
Latest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator Baxter Healthcare Corporation
- Developer National Resilience
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ross River virus infections
Most Recent Events
- 02 Oct 2017 Nanothearpeutics is now called Ology Bioservices
- 23 Apr 2013 Baxter completes a phase III follow-up trial for Ross River virus infections in Australia (NCT01604746)
- 31 Oct 2012 Baxter completes a phase III trial in Ross River virus infections in Australia (NCT01242670)